rs12510549 — SLC2A9

Intergenic variant in the SLC2A9 urate-transporter locus — the C allele is associated with lower serum uric acid levels and reduced gout risk

See your personal result for SLC2A9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC2A9 — The Uric Acid Thermostat

Uric acid11 Uric acid
The end product of purine metabolism in humans; unlike most mammals, humans lack the enzyme uricase and must excrete uric acid via the kidneys is a Jekyll-and-Hyde molecule. At normal concentrations it acts as an antioxidant, but when levels climb — whether through overproduction from purine-rich foods, alcohol, or fructose, or through impaired renal excretion — urate crystals precipitate in joints, causing the excruciating inflammation of gout22 gout
A form of inflammatory arthritis caused by monosodium urate crystal deposition in joints, most commonly the big toe, ankle, and knee. About 90% of hyperuricemia cases are due to reduced kidney excretion rather than overproduction, and SLC2A9 is one of the most important genes governing that excretion rate.

The SLC2A9 gene33 SLC2A9 gene
Solute Carrier Family 2 Member 9, also known as GLUT9, encodes a high-capacity urate transporter at the basolateral membrane of kidney proximal tubule cells encodes GLUT9, a facilitatory transporter that moves urate from renal proximal tubule cells back into the bloodstream — a reabsorption step that returns filtered urate to circulation rather than allowing it to be excreted in urine. Functional studies show GLUT9 transports urate at a Km of ~365 μM44 Functional studies show GLUT9 transports urate at a Km of ~365 μM
Anzai et al. 2008 — confirmed GLUT9 saturable urate efflux kinetics, making it the highest-capacity urate reabsorber identified in the kidney. Common variants in the SLC2A9 locus are the largest genetic determinants of serum uric acid levels identified by GWAS, explaining 1–3% of population variance — larger effects than any other single locus.

The Mechanism

rs12510549 maps to chromosome 4 at position 10,274,843 (GRCh38), in the intergenic region upstream of SLC2A9. It is an unannotated regulatory variant — no direct gene annotation in current Ensembl releases — but it sits within a dense cluster of SLC2A9-linked GWAS signals and is in moderate linkage disequilibrium with functional coding and intronic variants in the gene. The variant tags a haplotype associated with altered SLC2A9 transcriptional regulation in kidney and liver, both tissues with high GLUT9 expression. The T allele (reference, major) is associated with higher SLC2A9 expression or activity, leading to greater urate reabsorption and higher serum uric acid. The C allele (alternate, minor) is associated with reduced reabsorption and lower uric acid levels. Each copy of the minor C allele decreases serum uric acid by approximately 0.30–0.35 mg/dL55 Each copy of the minor C allele decreases serum uric acid by approximately 0.30–0.35 mg/dL
Brandstätter et al. 2008 — Diabetes Care cohort study confirming per-allele effect, consistent across European cohorts and representing a biologically meaningful shift given that the threshold for urate crystal formation is approximately 6.8 mg/dL.

The Evidence

Brandstätter et al. 200866 Brandstätter et al. 2008
Sex-specific association of SLC2A9 variants with uric acid modified by BMI. Diabetes Care. genotyped rs12510549 alongside three other SLC2A9 SNPs in 800 Bruneck Study participants and a Utah obesity cohort (n=1,869). Each C allele copy reduced uric acid by 0.30–0.35 mg/dL, with p-values reaching 10⁻¹⁴ to 10⁻²⁰ in fully adjusted analyses. Crucially, the effect was significantly stronger in women and was amplified by higher BMI — people with obesity showed larger per-allele uric acid differences than lean individuals.

Stark et al. 200877 Stark et al. 2008
Association of common GLUT9 polymorphisms with gout but not coronary artery disease. PLoS One. tested all four SLC2A9 SNPs in 665 gout cases versus 665 matched controls. All four SNPs showed highly significant association with gout; for the lead SNP rs6855911, the allelic OR was 0.62 (95% CI 0.52–0.75; p = 3.2 × 10⁻⁷). rs12510549 showed similar directionality. Notably, the same variants showed no association with coronary artery disease, indicating the SLC2A9 locus acts specifically through uric acid rather than broader metabolic effects.

Lee et al. 201788 Lee et al. 2017
Meta-analysis of SLC2A9 polymorphisms and gout susceptibility. Z Rheumatol. pooled 11 comparative studies comprising 1,472 gout patients and 3,269 controls. For rs12510549 specifically, the C allele showed an OR of 0.641 (95% CI 0.54–0.76; p = 4.1 × 10⁻⁷) in overall analysis, with the effect driven primarily by Caucasian populations (OR 0.647, p = 1.2 × 10⁻⁶). The Asian subgroup showed a protective trend (OR 0.515) but was not statistically significant, possibly due to lower minor allele frequency in East Asians (~12%) and smaller sample sizes in Asian cohorts.

A sex-age interaction noted by Brandstätter et al. 201099 Brandstätter et al. 2010
Sex and age interaction with genetic association of atherogenic uric acid concentrations. Atherosclerosis. — across 4,492 participants, the protective effect of the C allele on uric acid levels strengthens with increasing age in women, while attenuating with age in men. This is likely explained by estrogen's independent uricosuric effect: premenopausal women excrete more uric acid, masking genetic variation; after menopause, SLC2A9 genotype becomes more clinically relevant.

Practical Actions

The per-allele effect of 0.30–0.35 mg/dL is modest when viewed in isolation, but diet and lifestyle choices interact directly with the SLC2A9 transport system. Fructose and alcohol both acutely inhibit renal urate excretion — fructose via competition at urate transporters, alcohol via lactate accumulation that reduces tubular urate secretion. For TT homozygotes (about 65% of Europeans), who already have high urate reabsorption rates, these dietary inputs push uric acid levels disproportionately higher. Monitoring serum uric acid — especially after dietary changes or before adding purine-heavy protein sources — is the highest-value intervention for TT carriers.

Xanthine oxidase inhibitors (allopurinol, febuxostat) and uricosuric agents (probenecid, lesinurad) work regardless of SLC2A9 genotype but may be prescribed at different thresholds depending on baseline uric acid level, which is partly genetically determined.

Interactions

rs12510549 is in partial LD with several other SLC2A9 variants already in the platform: rs16890979 (Val282Ile, the main coding variant explaining the sex-specific urate effect), rs11942223 (intronic, independent second signal), and rs3733591 (Arg265His). Their combined effects on serum uric acid can be additive. The ABCG2 variant rs2231142 (Q141K) acts through a different mechanism — intestinal urate secretion rather than renal reabsorption — and compounds gout risk when co-occurring with high-risk SLC2A9 haplotypes. Users carrying both SLC2A9 T-risk haplotype and ABCG2 TT genotype face substantially elevated gout risk from both reduced intestinal excretion and increased renal reabsorption simultaneously.

Genotype Interpretations

What each possible genotype means for this variant.

CC Lower Urate Reabsorption Normal

Your SLC2A9 genotype is associated with lower uric acid levels and reduced gout risk

You carry two copies of the protective C allele at rs12510549, a genotype found in about 4% of Europeans. Each C allele reduces serum uric acid by approximately 0.30–0.35 mg/dL compared to the T allele, so CC homozygotes have uric acid levels roughly 0.60–0.70 mg/dL lower on average than TT homozygotes. The meta-analysis data show CC carriers have an OR of approximately 0.41 for gout compared to TT — meaning gout is about 2.4 times less likely. Your SLC2A9 genotype places you in a genetically favorable position regarding uric acid metabolism.

CT Intermediate Urate Reabsorption Intermediate

You carry one protective C allele — your uric acid levels are modestly lower than TT homozygotes

The additive inheritance pattern means TC heterozygotes experience approximately half the benefit of CC homozygotes — about 0.30–0.35 mg/dL lower uric acid than TT carriers on a per-allele basis. The Brandstätter 2008 data showed this effect is reproducible across multiple cohorts (p = 10⁻⁹ to 10⁻¹¹ for combined analysis).

The gout-protective effect in heterozygotes is statistically significant in large cohorts but is smaller in absolute terms than the TT vs CC comparison. Whether the TC genotype translates to clinical protection depends on your baseline uric acid (which is also influenced by rs16890979, rs11942223, and other SLC2A9 variants in LD), dietary habits, kidney function, BMI, and sex. Women with TC are at lower risk than men because estrogen provides additional uricosuric benefit; post-menopausal women with TC lose that hormonal buffer.

TT High Urate Reabsorption High Risk

Your SLC2A9 genotype is associated with higher serum uric acid levels and elevated gout risk

The TT genotype reflects a haplotype associated with higher GLUT9 expression or activity in renal proximal tubule cells, meaning more filtered urate is returned to the bloodstream rather than excreted in urine. The ~0.60–0.70 mg/dL elevation in uric acid may seem small, but it is clinically meaningful: the supersaturation threshold at which monosodium urate crystals form in synovial fluid is approximately 6.8 mg/dL. Moving a person from 5.8 to 6.5 mg/dL doesn't cause gout — but the same 0.7 mg/dL push from 6.5 to 7.2 mg/dL can tip them over the crystal-formation threshold.

The Brandstätter 2008 data showed that the per-allele urate effect is amplified by BMI: in individuals with obesity, the urate difference between TT and CC carriers is substantially larger than in lean individuals. This gene-environment interaction is important — the SLC2A9 genotype determines the set point, but diet and metabolic state determine how far above or below that set point you actually sit.

Women with TT genotype have somewhat less clinical risk before menopause due to estrogen's uricosuric effect, but post-menopause the genotype's contribution to uric acid becomes fully expressed.